Skip to main content
SpringerLink
Log in

Stoffwechsel II

  • Conference paper
90. Kongreß

Part of the book series: Verhandlungen der Deutschen Gesellschaft für Innere Medizin ((VDGINNERE,volume 90))

  • 31 Accesses

Zusammenfassung

Katecholamine spielen für die Mobilisation von Depotfett im Organismus eine wichtige Rolle. Im Gegensatz zu anderen Spezies vermag diese Hormonklasse beim Menschen die Freisetzung von Glyzerin und Fettsäuren aus dem Fettgewebe nicht nur zu stimulieren, sondern auch zu hemmen (Kather 1981). Die aktivierenden Wirkungen von Adrenalin und Noradrenalin werden über Beta-Rezeptoren vermittelt, die Hemmung der Depotfettmobilisation erfolgt über Alpha2-Rezeptoren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arner P, Engefeldt P, Nowak J (1981) In vivo observations on the lipolytic effect of noradrenaline during therapeutic fasting. J Clin Endocrinol Metab 53: 1207–1212

    Article  PubMed  CAS  Google Scholar 

  2. Hales CN, Lucio JP, Siddle K (1978) Hormonal control of adipose tissue lipolysis. Biochem Soc Symp 43: 97–135

    PubMed  CAS  Google Scholar 

  3. Kather H (1981) Hormonal regulation of adipose tissue lipolysis in man: Implications for the pathogenesis of obesity. Triangle 20: 131–143

    CAS  Google Scholar 

  4. Kather H, Schröder F, Simon B (1982) Microdetermination of glycerol using bacterial NADH-linked luciferase. Clin Chim Acta 120: 295–300

    Article  PubMed  CAS  Google Scholar 

  5. Kjellberg J, Östman J (1971) Lipolysis and glucose tolerance in obese subjects during prolonged starvation. Acta Med Scand 190: 191–198

    Google Scholar 

  6. Rodbell M ( 1964 ) Metabolism of isolated fat cells. J Biol Chem 239–384

    Google Scholar 

  7. Vasselli JR et al. (1983) Modern concepts of obesity. Nutr Rev 41: 361–373

    Article  PubMed  CAS  Google Scholar 

  8. Green H, Kehinde O (1975) An established preadipose cell-line and its differentiation in culture. II. Factors influencing the adipose conversion. Cell 5: 19–27

    Article  PubMed  CAS  Google Scholar 

  9. Kuri-Harcuch W, Green H (1978) Adipose conversion of 3T3 cells depends on a serum factor. Proc Natl Acad Sci USA 75: 6107–6109

    Article  PubMed  CAS  Google Scholar 

  10. Grimaldi P et al. (1982) Differentiation of ob 17 preadipocytes to adipocytes: requirement of adipose conversion factor(s) for fat cell cluster formation. EMBO J 1: 687–693

    PubMed  CAS  Google Scholar 

  11. Löffler G et al. (1983) An adipogenic serum factor in genetically obese rodents. FEBS Lett 153: 179–182

    Article  PubMed  Google Scholar 

  12. Morikawa M et al. (1982) Growth hormone and the adipose conversion of 3T3 cells. Cell 29: 783–789

    Article  PubMed  CAS  Google Scholar 

  13. Häussinger D (1983) Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem 133: 269–275

    Article  PubMed  Google Scholar 

  14. Häussinger D, Gerok W (1984) Hepatocyte heterogeneity in ammonia metabolism: impairment of glutamine synthesis in CCI4 induced liver cell necrosis with no effect on urea synthesis. Chem Biol Interact 48: 191–194

    Article  PubMed  Google Scholar 

  15. Häussinger D, Sies H (1979) Hepatic glutamine metabolism under the influence of the portal ammonia concentration in the perfused rat liver. Eur J Biochem 101: 179–184

    Article  PubMed  Google Scholar 

  16. Häussinger D, Gerok W, Sies H (1983) Regulation of flux through glutaminase and glutamine synthetase in isolated perfused rat liver. Biochim Biophys Acta 755: 272–278

    Article  PubMed  Google Scholar 

  17. Häussinger D, Sies H (1984) Effect of phenylephrine on glutamate and glutamine metabolism in isolated perfused rat liver. Biochem J (in press)

    Google Scholar 

  18. Atkinson DE, Camien MN (1982) The role of urea synthesis in the removal of metabolic bicarbonate and the regulation of blood pH. Curr Top Cell Regu121: 261–302

    Google Scholar 

  19. Oliver J, Koelz AM, Costello J, Bourke E (1977) Acid-base induced alterations in glutamine metabolism and ureogenesis in perfused muscle and liver of the rat. Eur J Clin Invest 7: 445–449

    Article  PubMed  CAS  Google Scholar 

  20. Häussinger D, Gerok W, Sies H (1984) Hepatic role in pH regulation. Role of the intercellular glutamine cycle. Trends Biochem Sci (in press)

    Google Scholar 

  21. Häussinger D, Akerboom TPM, Sies H (1980) The role of pH and the lack of a requirement for hydrogencarbonate in the regulation of hepatic glutamine metabolism. Hoppe Seylers Z Physiol Chem 361: 995–1001

    Article  PubMed  Google Scholar 

  22. Orrego H, Carmichael FJ, Phillips MJ, Kalant H, Khanna J, Israel Y (1976) Gastroenterology 71: 821–826

    PubMed  CAS  Google Scholar 

  23. Schanne FAX, Pfau RG, Farber JL (1980) Am J Pathol 100: 25–38

    PubMed  CAS  Google Scholar 

  24. Reichlin S (1983) N Engl J Med 309: 1556–1563

    Article  PubMed  CAS  Google Scholar 

  25. Limberg B, Kommerell B (1983) IRCS Med Sci 11: 572–573

    CAS  Google Scholar 

  26. Adler RD, Bennion LH, Duane WS et al. (1975) Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. Gastroenterology 68: 326–334

    PubMed  CAS  Google Scholar 

  27. Admirand WH, Small DM (1968) The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 47: 1043–1052

    Article  PubMed  CAS  Google Scholar 

  28. Angelin B, Einarsson K, Leijd B (1979) Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 9: 185–190

    Article  PubMed  CAS  Google Scholar 

  29. Angelin B, Einarsson K, Leijd B (1984) Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. Eur J Clin Invest 14: 73–78

    Article  PubMed  CAS  Google Scholar 

  30. Bateson MC, Maclean D, Ross PE et al. (1978) Clofibrate therapy and gallstone induction. Dig Dis 23: 623–628

    CAS  Google Scholar 

  31. Bartlett GR (1959) Phosphorous assay in column chromatography. J Biol Chem 234: 466–468

    PubMed  CAS  Google Scholar 

  32. Carey M, Small DM (1978) The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest 61: 998–1026

    Article  PubMed  CAS  Google Scholar 

  33. Creger PL, Moersch GW, Neuklis WA (1976) Structure activity relationship of gemfibrozil (CI-719) and related compounds. Proc R Soc Med (Suppl 2 ) 69: 3–5

    Google Scholar 

  34. Eggstein M, Kreutz FH (1966) Eine neue Bestimmung der Neutralfette in Blutserum and Gewebe. Klin Wochenschr 44: 262–266

    Article  PubMed  CAS  Google Scholar 

  35. Grundy SM, Ahrens EH Jr, Salen G et al. (1972) Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13: 531–551

    PubMed  CAS  Google Scholar 

  36. Grundy SM, Metzger AL (1972) A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology 62: 1200–1217

    PubMed  CAS  Google Scholar 

  37. Hall MJ, Nelson LM, Russel RI et al. (1981) Gemfibrozil–the effect on biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate. Atherosclerosis 39: 511–516

    Article  PubMed  CAS  Google Scholar 

  38. Hjermann I, Velve Byre K, Holme I, Leren P (1981) Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 2: 1303–1313

    Article  PubMed  CAS  Google Scholar 

  39. Hofmann AF, Grundy SM, Lachin JM et al. (1982) Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. Gastroenterology 83: 738–752

    PubMed  CAS  Google Scholar 

  40. Kaukola S, Manninen V, Malkonen M et al. (1981) Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Med Scand 209: 69–73

    Article  PubMed  CAS  Google Scholar 

  41. Kesaniemi YA, Grundy SM (1984) Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man. JAMA (in press)

    Google Scholar 

  42. Kissebah AH, Adams PA, Wynn V (1976) Lipokinetic studies with gemfibrozil (CI-719). Proc R Soc Med (Suppl 2 ) 69: 94–97

    Google Scholar 

  43. Lageder H, Irsigler K (1976) Evalution of increasing doses of gemfibrozil in hyperlipoproteinaemia. Proc R Soc Med (Suppl 2 ) 69: 71–75

    Google Scholar 

  44. LaRusso NF, Hoffman NE, Hofmann AF et al. (1975) Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients. Gastroenterology 69: 1301–1314

    PubMed  CAS  Google Scholar 

  45. Leiß O, von Bergmann K (1983) Zusammenhänge zwischen Serum-Lipoproteinstoffwechsel and biliärem Lipidstoffwechsel. Klin Wochenschr 61: 579–592

    Article  PubMed  Google Scholar 

  46. Leiß O, von Bergmann K (1984) Einfluß von Fenofibrat and Bezafibrat auf den biliären Lipidstoffwechsel. In: Kaffarnik H, Schneider J (Hrsg) Hyperlipoproteinämie. Pathophysiologie–Diagnostik–Therapie. perimed Fachbuch-Verlagsgesellschaft mbH, Erlangen, S 168–174

    Google Scholar 

  47. Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351–364

    Google Scholar 

  48. Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374

    Google Scholar 

  49. Lipid Research Clinics Program Manual of Laboratory Operations (1974) Department of Health, Education of Welfare Publication. NIH 75–628

    Google Scholar 

  50. Miettinen TA, Ahrens EH, Grundy SM (1965) Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res 6: 411–424

    PubMed  CAS  Google Scholar 

  51. Nair PP, Gordon M, Reback J (1967) The enzymic cleavage of the carbon-nitrogen bound in 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholan-25-oylglycine. J Biol Chem 242: 7–11

    PubMed  CAS  Google Scholar 

  52. Nash DT (1980) Gemfibrozil–a new lipid lowering agent. J Med 11: 107–116

    PubMed  CAS  Google Scholar 

  53. Nikkila EA, Ylikahri R, Huttunen JK (1976) Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med (Suppl 2 ) 69: 58–63

    Google Scholar 

  54. O’Connor RE (1982) Gemfibrozil–Results of clinical studies in the United States. In: Ricci G, Paoletti R, Pocchiari F, Poggiolini D (eds) Therapeutic selectivity and risk/benefit assessment of hypolipidemic drugs. Raven Press, New York, pp 59–61

    Google Scholar 

  55. Olsson AG, Roessner S, Wallding G et al. (1976) Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med (Suppl 2 ) 69: 28–31

    Google Scholar 

  56. Palmer RH (1978) Prevalence of gallstones in hyperlipidemia and incidence during treatment with clofibrate and/or cholestyramine. Trans Assoc Am Physicians 91: 424–432

    PubMed  CAS  Google Scholar 

  57. Paumgartner G, Horak W, Probst P et al. (1971) Effect of phenobarbital on bile flow and bile salt excretion in the rat. Naunyn-Schmiedebergs Arch Pharmako1270: 98–102

    Google Scholar 

  58. Pertsemlidis D, Panveliwalla D, Ahrens EH Jr (1974) Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 66: 565–573

    PubMed  CAS  Google Scholar 

  59. Report from the Committee of Principal Investigators (1978) A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 40: 1069–1118

    Article  Google Scholar 

  60. Roeschlau P, Bernt E, Gruber W (1974) Enzymatische Bestimmung des Gesamt-Cholesterins im Serum. Z Klin Chem Klin Biochem 12: 226–231

    PubMed  CAS  Google Scholar 

  61. Schlierf G, Chwat M, Feuerborn E et al. (1980) Biliary and plasma lipids and lipid-lowering chemotherapy–studies with clofibrate, fenofibrate and etofibrate in healthy volunteers. Atherosclerosis 36: 323–329

    Article  CAS  Google Scholar 

  62. Schlierf G, Fischer H, Roche A et al. (1980) Gallenlipide unter Bezafibrat. Münch Med Wochenschr 122: 165–168

    CAS  Google Scholar 

  63. Schwandt P, Weisweiler P, Neureuther G (1979) Serum lipoprotein lipids after gemfibrozil treatment. Artery 5: 117–124

    PubMed  CAS  Google Scholar 

  64. Sedaghat A, Grundy SM (1980) Cholesterol crystals and the formation of cholesterol gallstones. N Engl J Med 302: 1274–1277

    Article  PubMed  CAS  Google Scholar 

  65. Sedaghat A, Kesaniemi YA, Grundy SM (1983) Cholesterol crystals — a crucial link in formation of cholesterol gallstones. In: Paumgartner G, Stiehl A, Gerok W (eds) Bile acids and cholesterol in health and diseases. MTP Press, Lancaster, pp 43–53

    Google Scholar 

  66. Talalay P (1960) Enzymatic analysis of steroid hormones. Methods Biochem Anal 8: 114–143

    Google Scholar 

  67. The Coronary Drug Project Research Group (1975) Coronary drug project. Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381

    Article  Google Scholar 

  68. Van Berge Henegouwen GP, Allan RN, Hofmann AF et al. (1977) A facile hydrolysis-solvolysis procedure for conjugated bile acid sulfates. J Lipid Res 18: 118–122

    Google Scholar 

  69. Vessby B, Lithell H, Boberg J et al. (1976) Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial. Proc R Soc Med (Supp12) 69: 30–37

    Google Scholar 

  70. von Bergmann K, Leiss O (1984) Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipidemia. Eur J Clin Invest 14: 150–154

    Article  Google Scholar 

  71. von Bergmann K, Leiß O (1984) Unveröffentlichte Ergebnisse

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klin. Institut für Herzinfarktforschung, Med. Univ.-Klinik Heidelberg, Deutschland

    H. Kather, E. Wieland, B. Fischer & A. Wirth

  2. Institut für Biochemie, Universität Regensburg, Deutschland

    H. Hauner, P. Feick & G. Löffler

  3. Med. Univ.-Klinik Freiburg/Brsg, Deutschland

    D. Häussinger & W. Gerok

  4. Institut für Physiolog. Chemie I, Düsseldorf, Deutschland

    H. Sies

  5. Med. Univ.-Klinik Heidelberg, Deutschland

    B. Limberg & B. Kommerell

  6. Med. Univ.-Kliniken Bonn und Heidelberg, Deutschland

    O. Lea, K. von Bergmann, A. Gnasso & J. Augustin

Authors
  1. H. Kather
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Hauner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Feick
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Häussinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Sies
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. Gerok
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Limberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B. Kommerell
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. O. Lea
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K. von Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A. Gnasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J. Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kather, H. et al. (1984). Stoffwechsel II. In: 90. Kongreß. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 90. J.F. Bergmann-Verlag, Munich. https://doi.org/10.1007/978-3-642-85457-6_58

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85457-6_58

  • Publisher Name: J.F. Bergmann-Verlag, Munich

  • Print ISBN: 978-3-8070-0342-9

  • Online ISBN: 978-3-642-85457-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation